Covid-19: India says homegrown mRNA vaccine safe in early trial
Government authorities have approved further studies to test the vaccine's efficacy in a larger population
Indian pharmaceutical firm Gennova Biopharmaceuticals' Covid-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said on Tuesday.
Government authorities have also approved further studies to test the vaccine's efficacy in a larger population. Gennova plans to conduct a mid-stage study at about 10 to 15 sites and a late-stage trial at 22 to 27 sites in India.
The company's vaccine development, partly funded by the government, will utilise the clinical trial network under the biotechnology department of the Ministry of Science and Technology.
Gennova is also investing in scaling up its vaccine manufacturing capacity, the government statement added.
Its parent firm, Emcure Pharmaceuticals, filed draft papers with the market regulator for an initial public offering last week.
Government authorities have approved further studies to test the... READ MORE
Moreover, daily Covid recoveries have been higher than infections... READ MORE
The new cases were detected through 325,118 additional tests READ MORE
Domestic flights to also allow only fully vaccinated passengers READ MORE
Randomly chosen lucky customers will have their shopping basket paid... READ MORE
Significant chunk of Americans continue to refuse to take even one... READ MORE
Employees can avail the leaves till the event ends on March 31, 2022 READ MORE
Authorities often express their appreciation for residents' good acts ... READ MORE